<DOC>
	<DOCNO>NCT02821468</DOCNO>
	<brief_summary>A previous multicenter trial lead Bioiberica S.A. confirm efficacy safety DROGLICAN treatment osteoarthritis ( OA ) patient severe pain . The MOVES study phase IV , double blind , randomize non-inferiority trial compare efficacy safety fix dose combination glucosamine hydrochloride ( GH ) + chondroitin sulfate ( CS ) ( DROGLICAN ) versus celecoxib patient symptomatic knee OA moderate severe pain . This study conclude drug reduce WOMAC Pain subscale 50 % without significant difference group . Further , difference secondary outcome assess patient 's pain , functional capacity , stiffness , inflammation , joint swelling , effusion , overall quality life . This new exploratory trial aim evaluate beneficial effect DROGLICAN good health cartilage patient suffer knee osteoarthritis reveal qualitative assessment cartilage biochemical composition vivo .</brief_summary>
	<brief_title>Evaluation Evolution Imaging Markers Cartilage Degradation Patients With Knee Osteoarthritis Receiving DROGLICAN</brief_title>
	<detailed_description>This study post-marketing , open , exploratory , multicenter trial 2 parallel-groups patient suffer knee OA . Investigators private public hospital rheumatologist , general practitioner , articular disease specialist locate Belgium . After evaluation investigator control visit via site-patient registry , potential participant ask perform inclusion visit ( V1 ) . During visit , investigator assess eligibility patient . Eligible patient sign inform consent . The investigator make general evaluation ( demography , medical history , OA history , OA medication history , concomitant medication include `` rescue treatment '' ) pain evaluation . Synovial fluid collect case knee swell . Blood sample collect preselected clinical laboratory future biomarkers analysis . Patients ask perform MRI exam within 20 day follow inclusion visit represent MRI baseline . A standard X-ray perform image site last X-ray available respond high quality standard . For DROGLICAN arm , patient give investigational medicinal product ( IMP ) 6-month period via hospital pharmacy image acquisition perform . IMP intake begin right baseline MRI acquisition . Study arm attribution determine accord order enrolment investigate site use randomization list . All study subject ( receive DROGLICAN untreated control ) allow take paracetamol oral NSAIDs exclude COX2 inhibitor relief knee pain . Patients ask use `` rescue medication '' need trial , begin Paracetamol ( 3g/day ) NSAIDs second-line medication , tell reduce use feel need . The use rescue treatment month prior visit record investigator Case Report Form ( CRF ) . All treatment osteoarthritis forbidden course study . Patients return consultation 6 month ( V2 ) 12 month ( V3 ) . At visit , investigator make general evaluation , record concomitant medication include rescue medication , adverse event drop-outs . For DROGLICAN arm , compliance IMP assess count unused capsule within investigation kit bring back patient . At V2 , patient give IMP next 6 month . Patients ask return investigator unused capsule IMP next visit . Blood sample synovial fluid ( applicable ) collect future biomarkers analysis . MRI do 6 month ( V2 ) optionally 12 month ( V3 ) . Finally , optional X-ray might perform V3 depend result interim analysis . Monthly phone call make investigator assess encourage patient 's compliance ( DROGLICAN arm ) , record potential adverse event , new concomitant treatment and/or drop-off . Patients ' clinical data record visit CRF .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Femorotibial knee OA ( Uni bilateral ) Responding clinical radiological criterion American College Rheumatology ( ACR ) Symptomatic 6 month painful knee Radiological K &amp; L grade IIIII radiograph le 12 month Moderatetosevere knee pain : knee pain score evaluate Visual Analogue Scale ( VAS ) ( 0100 ) ≥ 40 last 24 hour inclusion visit ( painful knee consider ) Able follow instruction study Having sign informed consent Related OA pathology Recent trauma ( &lt; 1 month ) knee responsible symptomatic knee Concurrent articular disease interfere evaluation OA and/or pain articular dysplasia , aseptic osteonecrosis , acromegaly , Paget 's disease , hemophilia , hemochromatosis , chondromatosis , villonodular synovitis knee , seronegative spondyloarthropathy , rheumatoid arthritis , gouty arthritis , infectious arthritis , radiculalgia low limb , arteritis , etc . Radiological K &amp; L grade I IV Prosthesis target knee Related treatment Analgesics manage OA knee pain 24h inclusion visit Corticosteroids injection target knee month precede inclusion Hyaluronan injection target knee last 6 month Oral corticotherapy ≥ 5mg/day last 3 month Symptomatic slowacting drug ( SYSADs ) treatment ( Chondroitin , diacerein , glucosamine , soy avocado unsaponifiables ) last 3 month An anticipated need OA related medication duration trial ( Corticosteroids hyaluronan injection , Oral corticotherapy , Arthroscopy , analgesic authorize rescue treatment ) forbid trial Arthroscopy last 6 month Patients know allergy CS , GH , intolerance rescue treatment ( Paracetamol NSAIDs ) Patients allergy shellfish Related associated disease Severe uncontrolled disease ( liver renal failure , lung/heart severe disease , tumor , HIV… . ) Anticipated need surgical invasive procedure trial include prosthesis target knee Related patient Artialis ( study coordinator ) Bioiberica ( Sponsor ) 's employee Participation therapeutic clinical trial last 3 month Under guardianship judicial protection Pregnancy , breastfeeding , plan conception Women without menopause tubal ligation without contraception Related MRI Unable receive gadopentetate contrast agent injection contraindication : Acute chronic severe renal insufficiency ( glomerular filtration rate &lt; 30 mL/min/1.73m2 ) ; Acute renal insufficiency severity due hepatorenal syndrome perioperative liver transplantation period . Known anaphylactic reaction Gadolinium relate substance Risk group MRI scan due magnetic field contrast agent : Metal body : Pacemaker / Automatic Implantable Cardioverter Defibrillators / Implantable Cardioverter Defibrillators ( coronary defibrillator ) , Nervus vagus stimulator , Artificial heart valve ( depend type ) , Metal clip cerebral artery vein , Metal particles eye , Portacath , Metal stent , Hydrocephalic pump / insulin pump , Metal implant ; f/e screw , prosthesis , piercings . Claustrophobia , serious mobility problem ( Parkinson , tremor )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>